BE475500A - - Google Patents
Info
- Publication number
- BE475500A BE475500A BE475500DA BE475500A BE 475500 A BE475500 A BE 475500A BE 475500D A BE475500D A BE 475500DA BE 475500 A BE475500 A BE 475500A
- Authority
- BE
- Belgium
- Prior art keywords
- preparation
- atropine
- alkaloids
- scopolamine
- hyoscyamine
- Prior art date
Links
- 229930013930 alkaloids Natural products 0.000 claims description 45
- 238000002360 preparation method Methods 0.000 claims description 36
- 229930006677 A03BA01 - Atropine Natural products 0.000 claims description 23
- RKUNBYITZUJHSG-SPUOUPEWSA-N Atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 claims description 23
- 229960000396 Atropine Drugs 0.000 claims description 23
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 claims description 21
- STECJAGHUSJQJN-FWXGHANASA-N Scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 claims description 21
- 229960002646 scopolamine Drugs 0.000 claims description 21
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 claims description 18
- RKUNBYITZUJHSG-FXUDXRNXSA-N Hyoscyamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@H]3CC[C@@H](C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-FXUDXRNXSA-N 0.000 claims description 16
- 229960003210 hyoscyamine Drugs 0.000 claims description 16
- 229930005342 hyoscyamine Natural products 0.000 claims description 16
- 239000011780 sodium chloride Substances 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 12
- 150000003797 alkaloid derivatives Chemical class 0.000 claims description 10
- 229960002028 Atropine Sulfate Drugs 0.000 claims description 4
- JPKKQJKQTPNWTR-CHYDPLAESA-N CHEMBL3182372 Chemical compound O.OS(O)(=O)=O.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1.O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 JPKKQJKQTPNWTR-CHYDPLAESA-N 0.000 claims description 4
- WTGQALLALWYDJH-MOUKNHLCSA-N CHEMBL3185877 Chemical compound Br.C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 WTGQALLALWYDJH-MOUKNHLCSA-N 0.000 claims description 4
- 229960004173 Hyoscyamine hydrobromide Drugs 0.000 claims description 4
- 229960004499 Scopolamine Hydrobromide Drugs 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 3
- RKUNBYITZUJHSG-LGGPCSOHSA-N (8-methyl-8-azabicyclo[3.2.1]octan-3-yl) (2S)-3-hydroxy-2-phenylpropanoate Chemical compound C1([C@@H](CO)C(=O)OC2CC3CCC(C2)N3C)=CC=CC=C1 RKUNBYITZUJHSG-LGGPCSOHSA-N 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 description 17
- 239000000203 mixture Substances 0.000 description 14
- 206010061536 Parkinson's disease Diseases 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 230000002354 daily Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- -1 hyosciamine Chemical compound 0.000 description 6
- 239000004615 ingredient Substances 0.000 description 6
- 210000003169 Central Nervous System Anatomy 0.000 description 5
- 206010033799 Paralysis Diseases 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 2
- 229940008238 Amphetamine Sulfate Drugs 0.000 description 2
- 208000004547 Hallucinations Diseases 0.000 description 2
- 206010022437 Insomnia Diseases 0.000 description 2
- 208000002740 Muscle Rigidity Diseases 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 229960002734 amfetamine Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 230000002496 gastric Effects 0.000 description 2
- 230000002035 prolonged Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000220479 Acacia Species 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 206010002855 Anxiety Diseases 0.000 description 1
- 206010057666 Anxiety disease Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N D-sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 208000002173 Dizziness Diseases 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- GUBGYTABKSRVRQ-UUNJERMWSA-N Lactose Natural products O([C@@H]1[C@H](O)[C@H](O)[C@H](O)O[C@@H]1CO)[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1 GUBGYTABKSRVRQ-UUNJERMWSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 208000004840 Megacolon Diseases 0.000 description 1
- FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 1
- 210000003205 Muscles Anatomy 0.000 description 1
- 208000006550 Mydriasis Diseases 0.000 description 1
- 210000001747 Pupil Anatomy 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 210000002784 Stomach Anatomy 0.000 description 1
- CZMRCDWAGMRECN-GDQSFJPYSA-N Sucrose Natural products O([C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O1)[C@@]1(CO)[C@H](O)[C@@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-GDQSFJPYSA-N 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 201000005794 allergic hypersensitivity disease Diseases 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- PYHRZPFZZDCOPH-UHFFFAOYSA-N amphetamine sulfate Chemical compound OS(O)(=O)=O.CC(N)CC1=CC=CC=C1.CC(N)CC1=CC=CC=C1 PYHRZPFZZDCOPH-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 230000002567 autonomic Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000000881 depressing Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drugs Drugs 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000000796 hypoacidity Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003340 mental Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000006011 modification reaction Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000000505 pernicious Effects 0.000 description 1
- 230000003285 pharmacodynamic Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 230000000241 respiratory Effects 0.000 description 1
- 230000001020 rhythmical Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 230000002269 spontaneous Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000004936 stimulating Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
Landscapes
- Health & Medical Sciences (AREA)
- Emergency Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE475500A true BE475500A (es) |
Family
ID=124162
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE475500D BE475500A (es) |
Country Status (1)
| Country | Link |
|---|---|
| BE (1) | BE475500A (es) |
-
0
- BE BE475500D patent/BE475500A/fr unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tam et al. | Yohimbine: a clinical review | |
| CA2514948C (fr) | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament | |
| US6376550B1 (en) | Pharmaceutical compositions containing tramadol for migraine | |
| US20060154932A1 (en) | Pharmaceutical compositions and method of treating parkinson's disease | |
| JPH05503102A (ja) | 喘息の治療のための光学的純粋ｒ（−）アルブテロール | |
| JP2002518438A (ja) | 不安状態または鬱病による神経および行動変化の予防および／または治療のための神経保護組成物 | |
| EP2305225A1 (fr) | Utilisation de l'enantiomere (1s, 2r) du milnacipran pour la preparation d'un medicament | |
| CN1141937C (zh) | 含有曲马朵的药物组合物用于制备治疗偏头痛或类偏头痛的药物 | |
| BE897355A (fr) | Compositions analgestiques et anti-inflammatoires comprenant de l'ibuprofen | |
| CA2283122A1 (fr) | Compositions d'extraits de plantes, leur procede de preparation, et compositions pharmaceutiques les renfermant | |
| US20110117070A1 (en) | Compositions and methods for treating headache | |
| BE475500A (es) | ||
| EP0413694B1 (fr) | Preparations medicamenteuses cardio-protectrices comprenant l'amiodarone, un derive nitre, notamment le dinitrate d'isosorbide et facultativement un beta-bloqueur | |
| US5948806A (en) | Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan) | |
| EP0108017B1 (fr) | Association renfermant à titre de principes actifs, un analgésique central et la vitamine B12 ou un de ses analogues | |
| EP0671915B1 (fr) | Utilisation de l'idazoxan et ses derives pour la preparation d'un medicament destine au traitement de la maladie de parkinson et de son evolution | |
| FR2587213A1 (fr) | Medicament pour le traitement de la dependance aux psychostimulants | |
| WO1998035670A1 (fr) | Produit contenant de l'idazoxan et de la 1-dopa comme preparation pharmaceutique combinee utilise pour la maladie de parkinson | |
| WO2008010768A1 (en) | Method of treating and diagnosing restless legs syndrome and periodic limb movements during sleep and means for carrying out the method | |
| CA2696918C (fr) | Compose pour son utilisation dans le traitement des neuropathies peripheriques | |
| EP0287469B1 (fr) | Assocation renfermant à titre de principes actifs, un analgésique central et la forskoline | |
| FR2976807A1 (fr) | Composition pharmaceutique pour le traitement de la dependance chez l’etre humain | |
| WO2023233329A1 (en) | Use of 5-methoxy-2-aminoindan ("meai") in methods for treating cocaine addiction | |
| US20160374959A1 (en) | Treatment of early stage parkinson's disease with a hydroxytyrosol-containing polyphenol formulation | |
| WO1997027850A1 (fr) | Compositions comprenant l'amiodarone et le betaxolol |